| Bioactivity | KPLH1130 is a specific pyruvate dehydrogenase kinase (PDK) inhibitor, blocks macrophage polarization and attenuates proinflammatory responses. KPLH1130 improves glucose tolerance in HFD-fed mice[1]. | ||||||||||||
| Target | PDK | ||||||||||||
| Name | KPLH1130 | ||||||||||||
| CAS | 906669-07-6 | ||||||||||||
| Formula | C15H13N3O3 | ||||||||||||
| Molar Mass | 283.28 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Min BK, et al. Pyruvate Dehydrogenase Kinase Is a Metabolic Checkpoint for Polarization of Macrophages to the M1 Phenotype. Front Immunol. 2019 May 7;10:944. |
KPLH1130
CAS: 906669-07-6 F: C15H13N3O3 W: 283.28
KPLH1130 is a specific pyruvate dehydrogenase kinase (PDK) inhibitor, blocks macrophage polarization and attenuates proi
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.